ドラッグリポジショニングの世界市場

ドラッグリポジショニングの世界市場は2030年までに373億米ドルに達する

2024年に294億米ドルと推定されたドラッグリポジショニングの世界市場は、2024～2030年の分析期間においてCAGR 4.1%で成長し、2030年には373億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである「がん治療」は、CAGR 4.4%を記録し、分析期間終了時には203億米ドルに達すると予測されます。CNS Diseases Indication（中枢神経系疾患）セグメントは、分析期間中CAGR 4.3％で成長すると推定されます。

米国市場は80億米ドルと推定、中国はCAGR 7.5％で成長予測

米国のドラッグリポジショニング市場は2024年に80億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに76億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のドラッグリポジショニング市場- 主要動向と促進要因のまとめ

ドラッグリポジショニングが現代の治療薬で再注目されている理由とは？

ドラッグリポジショニングは、既存薬や以前は棚上げされていた医薬品の新たな治療用途を特定することを意味します。このアプローチは、製薬会社、研究者、保健当局が、満たされていない医療ニーズに対応するため、より迅速で費用対効果の高い方法を模索する中で、ルネッサンス期を迎えています。従来の医薬品開発には10年以上の時間と数十億の費用がかかり、臨床的に失敗する率も高いです。対照的に、リパーポーズされた医薬品は、安全性と薬物動態の重要なハードルをすでにクリアしているため、開発者は初期段階の試験を回避し、上市までの時間を大幅に短縮することができます。このため、特に希少疾患、腫瘍学、神経変性疾患、感染症などの分野において、リパーポーズは非常に魅力的な戦略となっています。

COVID-19の大流行は、レムデシビル、デキサメタゾン、ヒドロキシクロロキンなどの薬剤がSARS-CoV-2に対する有効性を迅速に評価されたため、リパーポージングへの関心をさらに高めました。この危機は、規制当局が緊急使用許可（EUA）を通じてリパーポーズされた医薬品をどのように迅速に進めることができるかを示し、加速された経路の新たな先例を浮き彫りにしました。さらに、サリドマイド（多発性骨髄腫の治療薬として再導入）やシルデナフィル（元々は高血圧の治療薬として開発され、現在では勃起不全の治療薬として広く使用されている）といった医薬品の成功は、この戦略が幅広い臨床的・商業的価値を持つことを実証しました。これらの例は、ドラッグリポジショニングが現代の医薬品研究開発において不可欠な要素であると見なされつつある理由を強調しています。

ドラッグリポジショニングを変革する新たな動向とは？

リパーポージング市場を再構築する大きな動向は、人工知能（AI）と機械学習（ML）の創薬パイプラインへの統合です。計算モデルは、ゲノムデータから実世界のエビデンスや電子カルテに至るまで、膨大なデータセットを分析し、新規の薬物-疾患関係を特定することができるようになりました。AI主導のプラットフォームは、化合物ライブラリーのインシリコ・スクリーニングを可能にし、前臨床および臨床評価のための候補化合物の優先順位付けを行う。これは特に希少疾患治療やプレシジョン・オンコロジーにおいて大きな効果を発揮します。希少疾患治療やプレシジョン・オンコロジーでは、患者数が限られており、研究開発コストが高いため、従来のパイプラインでは苦戦を強いられることが少なくありません。

共同コンソーシアムや官民パートナーシップも増加傾向にあります。NIHのNCATS（National Center for Advancing Translational Sciences）やOpen Targetsのようなイニシアチブは、学術界、産業界、政府間でデータやリソースをプールし、再利用の取り組みを加速させています。さらに、ブロックバスター医薬品の特許切れにより、ジェネリック医薬品や専門製薬企業によるリパーポージングへの新たな関心が高まっています。規制状況も進化しており、米国では505（b）（2）承認のための明確なガイダンスを提供する取り組みが、欧州ではアダプティブ・ライセンシング・モデルが、知的財産と臨床検証の状況をナビゲートしやすくしています。このような動向は、イノベーション、コラボレーション、そして疾患領域全体にわたる医薬品開発の加速のための肥沃な土壌を作り出しています。

リパーポーズ戦略から最も恩恵を受ける治療領域は？

ドラッグリポジショニングの影響は、複雑で十分な治療を受けていない治療領域において最も顕著です。例えば、がん領域では、アジュバントやセカンドライン治療としてリパーポーズ薬が検討されています。メトホルミン（糖尿病治療薬）、プロプラノロール（β遮断薬）、イトラコナゾール（抗真菌薬）は、様々な研究で抗がん剤の可能性を示しています。アルツハイマー病やパーキンソン病のような神経変性疾患では、炎症、コレステロール代謝、ミトコンドリア機能を標的とする薬剤が、新規治療が苦戦している疾患の進行を遅らせるために再配置されています。このリパーポージング・モデルは、既知の薬力学を活用して二次的な経路を標的とすることで、失敗の多い領域で新たな希望をもたらします。

感染症、特に抗菌薬耐性（AMR）が高まる中、リポジショニングされた抗ウイルス薬や抗生物質が重要なギャップを埋めつつあります。例えば、ある種の抗がん剤は予期せぬ抗菌・抗真菌作用を示し、精神科治療薬はウイルス感染における免疫調節の役割を研究されています。また、ループス、関節リウマチ、多発性硬化症などの自己免疫疾患や炎症性疾患も、他の疾患との重複経路が調査されるにつれて、その恩恵を受けることになります。メンタルヘルスの治療においても、治療抵抗性うつ病におけるケタミンの使用はその典型例です。このような治療分野横断的な応用は、多くのレガシー医薬品の価値提案を広げ、現代的な治療パラダイムへの再統合を後押ししています。

ドラッグリポジショニングの成長と戦略的投資の原動力は？

ドラッグリポジショニング市場の成長は、技術的有効化、規制の円滑化、進化する医薬品戦略に関連するいくつかの要因によって牽引されています。AIとバイオインフォマティクス・プラットフォームは、作用メカニズムを予測し、オフターゲット効果を高精度で特定することで、リパーポージング・プロジェクトの成功率を大幅に向上させています。オミックス・プロファイル、疾患登録、患者レベルのデータなど、大規模な生物医学データセットの利用可能性は、クロスインディケーション・マッピングや薬効モデリングのための肥沃な土壌を提供します。これらのテクノロジーは、従来、新薬開発に伴うリスク、コスト、時間を軽減します。

最終用途への採用も加速しています。バイオテクノロジー企業は、中核的なビジネスモデルとしてリパーポージングを追求する傾向を強めており、一方、大手製薬企業は、特許切れや低性能の資産の価値を拡大するために、リパーポージングをライフサイクルマネジメントに組み込んでいます。規制当局は、米国における505（b）（2）ルートのような合理化された承認経路を導入しており、開発者は既存の安全性と有効性のデータを活用できる一方、新たな適応症については補足的な臨床エビデンスを要求されるだけです。このため、ライセンシングやジョイントベンチャー、ベンチャーキャピタルによるリパーポージング事業への投資がしやすい環境が整っています。さらに、患者擁護団体や希少疾病財団がロビー活動を展開し、リパーポージング研究に資金を提供することで、認知度と臨床的機運の両方を高めています。これらの力が相まって、ドラッグリポジショニングは世界の医薬品イノベーション・エコシステムにおいて戦略的かつ急速に成長する柱であり続けています。

セグメント

適応疾患（がん、中枢神経系疾患、神経変性疾患、その他の適応疾患）、アプローチタイプ（疾患中心アプローチ、標的中心アプローチ、薬剤中心アプローチ）、エンドユーズ（病院・診療所、外来手術疾患、その他のエンドユーズ）

調査対象企業の例（注目の41社）

• AbbVie Inc.
• Algernon Pharmaceuticals
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• BioXcel Therapeutics Inc.
• Bristol-Myers Squibb Co.
• Every Cure
• Exscientia Ltd.
• GSK plc
• Healx Ltd.
• Johnson & Johnson
• Melior Discovery
• Novartis AG
• Pfizer Inc.
• Rejuvenate Biomed NV
• Retrotope Inc.
• SOM Biotech S.L.
• Tonix Pharmaceuticals
• United Therapeutics Corp.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Drug Repurposing Market to Reach US$37.3 Billion by 2030

The global market for Drug Repurposing estimated at US$29.4 Billion in the year 2024, is expected to reach US$37.3 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Oncology Indication, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$20.3 Billion by the end of the analysis period. Growth in the CNS Diseases Indication segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 7.5% CAGR

The Drug Repurposing market in the U.S. is estimated at US$8.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Drug Repurposing Market - Key Trends & Drivers Summarized

Why Is Drug Repurposing Gaining Renewed Attention in Modern Therapeutics?

Drug repurposing-also known as drug repositioning-involves identifying new therapeutic uses for existing or previously shelved drugs. This approach is experiencing a renaissance as pharmaceutical companies, researchers, and health authorities seek faster, more cost-effective pathways to address unmet medical needs. Traditional drug development can take over a decade and cost billions, with high rates of clinical failure. In contrast, repurposed drugs have already cleared significant safety and pharmacokinetic hurdles, enabling developers to bypass early-stage trials and significantly reduce time to market. This has made repurposing a highly attractive strategy, particularly in areas like rare diseases, oncology, neurodegenerative disorders, and infectious diseases.

The COVID-19 pandemic further propelled interest in repurposing, as drugs like remdesivir, dexamethasone, and hydroxychloroquine were rapidly evaluated for efficacy against SARS-CoV-2. The crisis showcased how regulatory bodies could fast-track repurposed drugs through Emergency Use Authorizations (EUAs), highlighting a new precedent for accelerated pathways. Furthermore, the success of drugs such as thalidomide (reintroduced for multiple myeloma) and sildenafil (originally developed for hypertension, now widely used for erectile dysfunction) have demonstrated the broad clinical and commercial value of this strategy. These examples underscore why drug repurposing is increasingly viewed as a vital component of modern pharmaceutical R&D.

What Are the Emerging Trends Transforming the Drug Repurposing Landscape?

A major trend reshaping the repurposing market is the integration of artificial intelligence (AI) and machine learning (ML) into drug discovery pipelines. Computational models can now analyze massive datasets-ranging from genomic data to real-world evidence and electronic health records-to identify novel drug-disease relationships. AI-driven platforms are enabling in silico screening of compound libraries to prioritize candidates for preclinical and clinical evaluation. This is especially impactful in rare disease treatment and precision oncology, where traditional pipelines often struggle due to limited patient populations and high R&D costs.

Collaborative consortia and public-private partnerships are also on the rise. Initiatives like the NIH’s NCATS (National Center for Advancing Translational Sciences) and Open Targets are pooling data and resources across academia, industry, and government to accelerate repurposing efforts. Additionally, patent expiration of blockbuster drugs is fueling new interest in repurposing by generics and specialty pharma companies. Regulatory frameworks are evolving too-efforts to provide clearer guidance for 505(b)(2) approvals in the U.S. and adaptive licensing models in Europe are making it easier to navigate the intellectual property and clinical validation landscape. These trends are creating fertile ground for innovation, collaboration, and accelerated drug development across disease areas.

Which Therapeutic Areas Are Benefiting Most from Repurposing Strategies?

The impact of drug repurposing is most visible in complex and underserved therapeutic areas. In oncology, for instance, repurposed drugs are being explored as adjuvants or second-line treatments. Metformin (a diabetes drug), propranolol (a beta-blocker), and itraconazole (an antifungal) have shown anticancer potential in various studies. In neurodegenerative diseases like Alzheimer’s and Parkinson’s, drugs targeting inflammation, cholesterol metabolism, and mitochondrial function are being repositioned to slow disease progression-areas where novel therapies have struggled. This repurposing model offers new hope in high-failure domains by leveraging known pharmacodynamics to target secondary pathways.

In infectious diseases, especially with rising antimicrobial resistance (AMR), repositioned antivirals and antibiotics are filling critical gaps. For example, certain anticancer agents have shown unexpected antibacterial or antifungal effects, while psychiatric drugs are being investigated for their immunomodulatory roles in viral infections. Autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, and multiple sclerosis, also stand to benefit, as researchers uncover overlapping pathways with other disease classes. Even mental health treatments are seeing cross-utility-ketamine’s use in treatment-resistant depression is a prime example. These cross-therapeutic applications are broadening the value proposition of many legacy drugs, supporting their reintegration into modern treatment paradigms.

What Is Driving Growth and Strategic Investment in Drug Repurposing?

The growth in the drug repurposing market is driven by several factors related to technological enablement, regulatory facilitation, and evolving pharmaceutical strategies. AI and bioinformatics platforms are significantly improving the success rate of repurposing projects by predicting mechanisms of action and identifying off-target effects with high precision. The availability of large-scale biomedical datasets-including omics profiles, disease registries, and patient-level data-provides fertile ground for cross-indication mapping and drug efficacy modeling. These technologies reduce the risk, cost, and time traditionally associated with de novo drug development.

End-use adoption is also accelerating. Biotechnology firms are increasingly pursuing repurposing as a core business model, while large pharma companies are integrating repurposing into life-cycle management to extend the value of off-patent or low-performing assets. Regulatory bodies are introducing streamlined pathways for approvals-such as the 505(b)(2) route in the U.S.-which allows developers to leverage existing safety and efficacy data while only requiring supplemental clinical evidence for new indications. This has created a favorable environment for licensing, joint ventures, and venture capital investment in repurposing ventures. Furthermore, patient advocacy groups and rare disease foundations are lobbying for and funding repurposing studies, driving both awareness and clinical momentum. These combined forces are ensuring that drug repurposing remains a strategic and rapidly growing pillar in the global pharmaceutical innovation ecosystem.

SCOPE OF STUDY:

The report analyzes the Drug Repurposing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Indication (Oncology, CNS Diseases, Neurodegenerative Diseases, Other Disease Indications); Approach Type (Disease-Centric Approach, Target-Centric Approach, Drug-Centric Approach); End-Use (Hospitals & Clinics, Ambulatory Surgery Diseases, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Algernon Pharmaceuticals
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• BioXcel Therapeutics Inc.
• Bristol-Myers Squibb Co.
• Every Cure
• Exscientia Ltd.
• GSK plc
• Healx Ltd.
• Johnson & Johnson
• Melior Discovery
• Novartis AG
• Pfizer Inc.
• Rejuvenate Biomed NV
• Retrotope Inc.
• SOM Biotech S.L.
• Tonix Pharmaceuticals
• United Therapeutics Corp.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Drug Repurposing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Cost-Efficiency Advantages of Drug Repurposing Accelerate R&D in Rare and Neglected Diseases
  • Growing Pressure to Reduce Development Timelines Spurs Interest in Repurposing Existing Molecules
  • Advancements in Bioinformatics and AI Algorithms Propel Discovery of New Indications for Known Drugs
  • Surging Demand for Affordable Therapeutics Drives Market Expansion for Repurposed Drug Candidates
  • Pharma Industry Shift Toward Risk Minimization Supports Investment in Drug Repositioning Portfolios
  • Increased FDA Approvals of Repurposed Drugs Validate Regulatory Pathways and Business Models
  • Pandemic-Driven Focus on Fast-Track Therapies Propels Global Awareness of Drug Repurposing Benefits
  • Integration of Omics Technologies and Patient Data Analytics Enhances Target Identification
  • Partnerships Between Biotech Startups and Academic Institutions Accelerate Pipeline Development
  • AI-Powered Drug Repurposing Platforms Expand Addressable Market Across Chronic Conditions
  • Growing VC Funding in Life Sciences Strengthens Commercial Viability of Repurposing Models
  • Patent Expiry Pressures Encourage Pharma Companies to Extend Value of Existing Assets via New Indications
  • Increased Public and Private Grant Support for Rare Disease Therapies Fuels Repurposing Projects
  • Surging Demand for Personalized Therapies Promotes Indication-Specific Repurposing Approaches
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Drug Repurposing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Drug Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for CNS Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for CNS Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for CNS Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Ambulatory Surgery Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Ambulatory Surgery Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Disease-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Disease-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Disease-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Target-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Target-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Target-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Drug-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Drug-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Drug-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• JAPAN
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• CHINA
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• EUROPE
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Drug Repurposing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• FRANCE
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• GERMANY
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Drug Repurposing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• INDIA
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Drug Repurposing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Drug Repurposing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
• AFRICA
  • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030

IV. COMPETITION